MUTATIONS AFFECTING THE ACTIVITY OF UROKINASE-TYPE PLASMINOGEN-ACTIVATOR

被引:3
|
作者
DAVIDOW, LS [1 ]
DUMAIS, DR [1 ]
SMYTH, AP [1 ]
GREER, J [1 ]
MOIR, DT [1 ]
机构
[1] ABBOTT LABS, COMP ASSISTED MOLEC DESIGN GRP, ABBOTT PK, IL 60064 USA
来源
PROTEIN ENGINEERING | 1991年 / 4卷 / 08期
关键词
PLASMINOGEN ACTIVATORS; PROUROKINASE; SCU-PA; SERINE PROTEASES; UROKINASE;
D O I
10.1093/protein/4.8.923
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Mutagenesis throughout the single-chain urokinase-type plasminogen activator (scu-PA) cDNA molecule, followed by expression of the mutant genes and secretion of the resulting mutant proteins from yeast, has been used to determine the amino acid residues important for activity of scu-PA molecules. Twelve out of 13 colonies secreting variant scu-PA molecules with decreased ability to form a zone of fibrinolysis had mutant genes with a single codon alteration in the serine protease encoding domain (B-chain). Many of these changes are of highly conserved residues in the serine proteases and are consequently of considerable interest. A model three-dimensional structure of the protease domain of urokinase was used to explain the basis for the effects of these down mutations. The model showed that the strongest down mutations result from either interference of the mutated side chain with substrate binding at the active site or the introduction of bulky or charged groups at structurally sensitive internal positions in the molecule. Attempts to find second site revertants of five down mutants, altered either at the plasmin activation site or near the serine at the active site, only resulted in same-site revertants, with the original or closely related amino acids restored.
引用
收藏
页码:923 / 928
页数:6
相关论文
共 50 条
  • [1] MODULATION OF LIPOXIDASE ACTIVITY BY UROKINASE-TYPE PLASMINOGEN-ACTIVATOR
    VANASWEGEN, CH
    DUTOIT, PJ
    DUPLESSIS, DJ
    PROSTAGLANDINS LEUKOTRIENES AND ESSENTIAL FATTY ACIDS, 1994, 51 (03): : 183 - 186
  • [2] UROKINASE-TYPE PLASMINOGEN-ACTIVATOR AND MALIGNANCY
    DUFFY, MJ
    FIBRINOLYSIS, 1993, 7 (05) : 295 - 302
  • [3] UROKINASE-TYPE PLASMINOGEN-ACTIVATOR, UROKINASE-TYPE PLASMINOGEN-ACTIVATOR RECEPTOR AND PLASMINOGEN-ACTIVATOR INHIBITOR-1 I IN BREAST-CANCER CELLS
    WAJIMA, T
    DEGEN, D
    ORIZ, V
    VONHOFFOLIN, DD
    THROMBOSIS AND HAEMOSTASIS, 1995, 73 (06) : 1284 - 1284
  • [4] THE CHICKEN UROKINASE-TYPE PLASMINOGEN-ACTIVATOR GENE
    LESLIE, ND
    KESSLER, CA
    BELL, SM
    DEGEN, JL
    JOURNAL OF BIOLOGICAL CHEMISTRY, 1990, 265 (03) : 1339 - 1344
  • [5] A CELLULAR RECEPTOR FOR UROKINASE-TYPE PLASMINOGEN-ACTIVATOR
    BELIN, D
    BACCINO, D
    WOHLWEND, A
    ESTREICHER, A
    HUARTE, J
    VASSALLI, JD
    THROMBOSIS AND HAEMOSTASIS, 1987, 58 (01) : 46 - 46
  • [6] THE MURINE UROKINASE-TYPE PLASMINOGEN-ACTIVATOR GENE
    DEGEN, SJF
    HECKEL, JL
    REICH, E
    DEGEN, JL
    BIOCHEMISTRY, 1987, 26 (25) : 8270 - 8279
  • [7] Characterization of the murine plasminogen/urokinase-type plasminogen-activator system
    Lijnen, HR
    VanHoff, B
    Collen, D
    EUROPEAN JOURNAL OF BIOCHEMISTRY, 1996, 241 (03): : 840 - 848
  • [8] DIFFERENTIAL DETECTION OF SINGLE CHAIN UROKINASE-TYPE PLASMINOGEN-ACTIVATOR AND 2 CHAIN UROKINASE-TYPE PLASMINOGEN-ACTIVATOR IN HUMAN AND MONKEY PLASMA
    MOLINARI, A
    GIORGETTI, C
    BONOMINI, L
    GERNA, M
    LANSEN, J
    GUREWICH, V
    FIBRINOLYSIS, 1992, 6 (01) : 17 - 26
  • [9] EXPRESSION OF UROKINASE-TYPE PLASMINOGEN-ACTIVATOR AND PLASMINOGEN-ACTIVATOR INHIBITOR IN COLON-DISEASE
    MISELJIC, S
    GALANDIUK, S
    MYERS, SD
    WITTLIFF, JL
    JOURNAL OF CLINICAL LABORATORY ANALYSIS, 1995, 9 (06) : 413 - 417
  • [10] ON THE REVERSIBLE INTERACTION OF PLASMINOGEN-ACTIVATOR INHIBITOR-1 WITH TISSUE-TYPE PLASMINOGEN-ACTIVATOR AND WITH UROKINASE-TYPE PLASMINOGEN-ACTIVATOR
    LIJNEN, HR
    VANHOEF, B
    COLLEN, D
    JOURNAL OF BIOLOGICAL CHEMISTRY, 1991, 266 (07) : 4041 - 4044